, Volume 8, Issue 2, pp 175–176 | Cite as

Should the Philosophy of Postmarketing Surveillance in the US be Redefined?

  • Javier Soto
  • J. A. Sacristan


Clinical Ethic Scientific Rigour Ethic Consultant Daily Medical Practice Drug Promotion 


  1. 1.
    La Puma J. Physician rewards for postmarketing surveillance (seeding studies) in the US. PharmacoEconomics 1995; 7 (3): 187–90PubMedCrossRefGoogle Scholar
  2. 2.
    Members ofthe ASCPT Pharmacoepidemiology Section. Notes of the American Society for Clinical Pharmacology and Therapeutics: position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clin Pharmacol Ther 1990; 48: 598CrossRefGoogle Scholar
  3. 3.
    Jefferys DB, Jones KH. EMEA and the new pharmaceutical procedures for Europe. Eur J Clin Pharmacol 1995; 47: 471–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Javier Soto
    • 1
  • J. A. Sacristan
    • 2
  1. 1.Pharmacoepidemiology Unit, Medical DepartmentAbbott Laboratories S.A.MadridSpain
  2. 2.Pharmacoepidemiology and Pharmacoeconomics, Unit, Clinical Research DepartmentLilly S.A.MadridSpain

Personalised recommendations